EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Irinotecan Modulates Immune Checkpoints in Neuroblastoma

Tom Lapidus iD, Elina Zorde-Khvalevsky, Alaa Jolani, Gal Goldstein, Amnon Peled

ImmunoTargets and Therapy · 2026-06 · Volume 15 · 1-15

DOI: 10.2147/itt.s598469 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ImmunoTargets and Therapy, 2026-06. Verfasst von Tom Lapidus und 4 weiteren Autor:innen. Beteiligte Einrichtung: Goldyne Savad Institute of Gene Therapy, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neuroblastoma (NBL) is the most common extracranial solid tumor in children, with a 50% survival rate in high-risk cases. Chemotherapy combination with immunotherapy is central to HR-NBL treatment.

Aim

This study aimed to explore how Irinotecan influences the immune landscape of NBL cells, particularly focusing on the modulation of immune checkpoints relevant to future chemo-immunotherapy strategies.

Methods

Two neuroblastoma cell lines, SK-N-BE(2) and SH-SY5Y, were exposed to sub-lethal doses of Irinotecan and IFN-γ. Flow cytometry assessed the expression of immune markers, including GD2, CD47, MHC I, and PD-L1. We also examined phagocytosis by macrophages and T-cell-mediated killing. In vivo studies using a neuroblastoma mouse model assessed the effects of Irinotecan and PBMC injections. Soluble CD47 was also measured in cell culture supernatants and exploratory patient plasma samples.

Results

Treatment exposure was associated with modulation of several immune-related markers, including GD2, CD47, PD-L1, and MHC class I. While Irinotecan reduced macrophage-mediated phagocytosis, this effect was reversed by the addition of anti-CD47 antibodies. T-cell-mediated killing was enhanced when NBL cells were pre-treated with Irinotecan. In vivo studies showed that the combination of PBMCs and Irinotecan resulted in reduced tumor burden compared to either treatment alone. Furthermore, CD47 expression was detectable in-patient plasma, suggesting that soluble CD47 may warrant exploration in larger future cohorts.

Conclusion

This pilot study suggests that irinotecan may modulate key immune checkpoints in neuroblastoma. These results supports further investigation of rational chemo-immunotherapy combinations, including GD2 and CD47-targeted combination strategies.

Schlagwörter

Stichwörter der Autor:innen

CD47chemotherapyimmunotherapyirinotecanneuroblastoma

Autor:innen und Institutionen

  • Goldyne Savad Institute of Gene Therapy, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
  • The Pediatric Hemato-Oncology Department, Hadassah- Hebrew University Medical Center, Jerusalem, Israel.

ORCID-Profile: Tom Lapidus

Zitieren

APA

Lapidus, T., Zorde-Khvalevsky, E., Jolani, A., Goldstein, G., & Peled, A. (2026). Irinotecan Modulates Immune Checkpoints in Neuroblastoma. ImmunoTargets and Therapy, Volume 15, 1-15. https://doi.org/10.2147/itt.s598469

Vancouver

Lapidus T, Zorde-Khvalevsky E, Jolani A, Goldstein G, Peled A. Irinotecan Modulates Immune Checkpoints in Neuroblastoma. ImmunoTargets and Therapy. 2026;Volume 15:1-15. doi:10.2147/itt.s598469

BibTeX
@article{Lapidus2026,
  author = {Lapidus, Tom and Zorde-Khvalevsky, Elina and Jolani, Alaa and Goldstein, Gal and Peled, Amnon},
  title = {Irinotecan Modulates Immune Checkpoints in Neuroblastoma},
  journal = {ImmunoTargets and Therapy},
  year = {2026},
  volume = {Volume 15},
  pages = {1--15},
  doi = {10.2147/itt.s598469}
}
Kostenlos starten →